A Phase 1 Dose-Escalation Study of Elesclomol Sodium Administered Intravenously to Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Trial Profile

A Phase 1 Dose-Escalation Study of Elesclomol Sodium Administered Intravenously to Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2014

At a glance

  • Drugs Elesclomol (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Synta Pharmaceuticals
  • Most Recent Events

    • 31 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
    • 31 Jan 2014 Planned End Date changed from 1 Sep 2012 to 1 Aug 2014 according to ClinicalTrials.gov record.
    • 08 Feb 2011 The first patient has been treated, according to a Synta Pharmaceuticals media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top